Newark, New Castle, USA, May 31, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global 5-alpha-reductase inhibitors (5-ARIs) marketwas conducted by Growth Plus Reports in 2022. The market is ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years ...

Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha reductase inhibitor dutasteride. Eur Urol. 2003;44 (4):461-466. 34.

Finasteride is a 5-alpha-reductase inhibitor, which blocks the conversion of testosterone into DHT. This means there’s more testosterone in your body.

Background: Active surveillance (AS) is a recognized management option for low-risk prostate cancer. Many institutions use serial PSA values to determine when to reclassify patients into higher risk ...

The 5-alpha reductase inhibitors and vitamin E and selenium have been the best studied. SELECT evaluated vitamin E and selenium and failed to show any reduction in the diagnosis of prostate cancer. 20 ...

Use of 5-alpha-reductase inhibitors (5-ARIs) by men on active surveillance (AS) for prostate cancer is associated with a lower likelihood of definitive treatment and pathologic progression ...

Current use of 5-alpha reductase inhibitors (5-ARI) is another reason to perform a biopsy for prostate cancer, investigators suggested in a poster presentation during the AUA2021 Virtual Experience.

Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44 (4):461-466.